Combined targeting of HER2 and VEGFR2 for effective treatmentof HER2-amplified breast cancer brain metastases

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 45, 2012, Pages

  Kodack, David P ^a   Chung, Euiheon ^a,b   Yamashita, Hiroshi ^a   Incio, Joao ^a   Duyverman, Annique M M J ^a   Song, Youngchul ^a   Farrar, Christian T ^a   Huang, Yuhui ^a   Ager, Eleanor ^a   Kamoun, Walid ^a   Goel, Shom ^a   Snuderl, Matija ^a   Lussiez, Alisha ^a   Hiddingh, Lotte ^a   Mahmood, Sidra ^a   Tannous, Bakhos A ^a   Eichler, April F ^c   Fukumura, Dai ^a   Engelman, Jeffrey A ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiangiogenesis; Targeted therapy; Treatment resistance; Tumor microenvironment; Tumor Stroma interaction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MONOCLONAL ANTIBODY DC101; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; BRAIN NECROSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VESSELS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL DEATH; CELL PROLIFERATION; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; FEMALE; GENE AMPLIFICATION; HUMANS; KILLER CELLS, NATURAL; MICE; MOLECULAR TARGETED THERAPY; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868595744     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216078109     Document Type: Article

References (38)

1. Lin NU, Winer EP (2007) Brain metastases: The HER2 paradigm. Clin Cancer Res 13(6): 1648-1655. (Pubitemid 46952930)
2. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27(31):5278- 5286.
3. Brufsky AM, et al. (2011) Central nervous system metastases in patients with HER2- positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14):4834-4843.
4. Pestalozzi B, et al. (2011) Trastuzumab does not increase the incidence of central nervous system (CNS) relapse in HER2-positive early breast cancer: The HERA trial experience. Cancer Res 71(24, Suppl 3):P4-17-01.
5. Palmieri D, et al. (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67(9):4190-4198. (Pubitemid 46815065)
6. Stemmler HJ, et al. (2006) Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15(2):219-225.
7. Sledge GW, Jr. (2011) HER2011: The changing face of HER2-positive breast cancer. Clin Breast Cancer 11(1):9.
8. Geyer CE, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733-2743. (Pubitemid 46021510)
9. Lin NU, et al. (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12): 1993-1999.
10. Lin NU, et al. (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452-1459.
11. Eichler AF, et al. (2011) The biology of brain metastases-Translation to new therapies. Nat Rev Clin Oncol 8(6):344-356.
12. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273-286.
13. Kumar S, et al. (1999) Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59(4):856-861. (Pubitemid 29086739)
14. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368-4380.
15. Miller K, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676.
16. Martín M, et al. (2012) Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist 17(4):469-475.
17. Besse B, et al. (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16(1):269-278.
18. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416(6878):279-280. (Pubitemid 34260234)
19. Fukumura D, et al. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6):715-725. (Pubitemid 28436004)
20. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D (1998) Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 5(3):271-278.
21. du Manoir JM, et al. (2006) Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12(3 Pt 1):904-916.
22. Le XF, et al. (2008) Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23): 3747-3758.
23. Witte L, et al. (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17(2):155-161. (Pubitemid 28391949)
24. Chung E, et al. (2009) Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4(12): e8316.
25. Konecny GE, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66(3):1630-1639. (Pubitemid 43259947)
26. Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27(34):5838-5847.
27. Hurvitz SA, et al. (2012) Analysis of Fcã receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 18(12):3478-3486.
28. Xia W, et al. (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24(41):6213-6221. (Pubitemid 43080044)
29. Garrett JT, et al. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 108(12):5021-5026.
30. Guarneri V, et al. (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study. J Clin Oncol 30(16):1989-1995.
31. Blackwell KL, et al. (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J Clin Oncol 30(21): 2585-2592.
32. Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21(2):107-112.
33. Cruz-Muñoz W, Kerbel RS (2011) Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol 21(2):123-130.
34. Kienast Y, et al. (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16(1):116-122.
35. Bos PD, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009.
36. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347):298-307.
37. Huang Y, et al. (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109:17561-17566.
38. Wurdinger T, et al. (2008) A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 5(2):171-173. (Pubitemid 351181745)